- Conditions
- Epilepsy
- Interventions
- USL255, Placebo
- Drug
- Lead sponsor
- Upsher-Smith Laboratories
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Ventura, California • Gainesville, Florida + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1993–2016
of 5,352
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
- Interventions
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 791
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 512 more
- Conditions
- Localized Osteosarcoma, Metastatic Osteosarcoma
- Interventions
- Cisplatin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate, Peginterferon Alfa-2b, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery
- Drug · Biological · Other + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more
- Conditions
- Arrhythmias, Cardiac
- Interventions
- Reveal LINQ
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 19
- States / cities
- San Francisco, California • Jacksonville, Florida • Tampa, Florida + 16 more
- Conditions
- Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Elastography, Multigated Acquisition Scan, Nivolumab, Sargramostim
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2033
- U.S. locations
- 763
- States / cities
- Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 494 more
- Conditions
- Hematopoietic Cell Transplant, Solid Organ Transplant, Respiratory Viral Infection
- Interventions
- Not listed
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Washington D.C., District of Columbia + 20 more
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Tesevatinib
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 62 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Denver, Colorado • Kansas City, Kansas + 8 more
- Conditions
- Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic, Aneurysmal Disease, Aorta, Thoracic Pathologies
- Interventions
- Rapidlink
- Device
- Lead sponsor
- Vascutek Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,877 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 928
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 589 more
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Medical Chart Review
- Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Not listed
- Enrollment
- 2,240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 629
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 405 more
- Conditions
- Acute Ischemic Stroke, Diabetes, Hyperglycemia
- Interventions
- IV insulin to maintain target glucose concentration of 80-130 mg/dL, Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 70
- States / cities
- Tucson, Arizona • Long Beach, California • Los Angeles, California + 45 more
- Conditions
- Atrial Fibrillation
- Interventions
- Intra-Cardiac Echocardiography guided Cardioversion, Intracardiac Echo, ICE
- Device
- Lead sponsor
- EP MedSystems
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 5
- States / cities
- Jacksonville, Florida • Chicago, Illinois • Urbana, Illinois + 2 more
- Conditions
- Steroid-refractory Acute Graft-versus-Host Disease, Treatment-refractory Acute Graft-versus-Host Disease
- Interventions
- Neihulizumab (ALTB-168)
- Biological
- Lead sponsor
- AltruBio Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 13
- States / cities
- Duarte, California • Los Angeles, California • Miami, Florida + 10 more
- Conditions
- Prostate Cancer
- Interventions
- Dendritic cell immunotherapy
- Drug
- Lead sponsor
- Northwest Biotherapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 16
- States / cities
- Springdale, Arkansas • Los Angeles, California • San Diego, California + 13 more
- Conditions
- Crohn's Disease
- Interventions
- Filgotinib, Placebo
- Drug · Other
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 101
- States / cities
- Dothan, Alabama • Sun City, Arizona • Coronado, California + 82 more
- Conditions
- Diabetes Mellitus, Type 2, Chronic Kidney Disease
- Interventions
- Semaglutide, Placebo (Semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Los Angeles, California • National City, California + 14 more
- Conditions
- Coronary Artery Disease
- Interventions
- pexelizumab in conjunction with CABG
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 182
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 129 more
- Conditions
- HIV Infection
- Interventions
- TMC114
- Drug
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 23 more
- Conditions
- Depression, Depressive Disorder
- Interventions
- Cortical Stimulation, Sham
- Device
- Lead sponsor
- Northstar Neuroscience
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Pittsburgh, Pennsylvania • Milwaukee, Wisconsin
- Conditions
- Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases
- Interventions
- Radiation therapy
- Radiation
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 3
- States / cities
- Pittsburgh, Pennsylvania • Houston, Texas • Milwaukee, Wisconsin
- Conditions
- Bladder Cancer
- Interventions
- valrubicin
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 10
- States / cities
- Tampa, Florida • Urbana, Illinois • East Orange, New Jersey + 5 more
- Conditions
- Cognitive Dysfunction, Memory Impairment
- Interventions
- Donepezil 5 mg, Placebo
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 278
- States / cities
- Anaheim, California • Antioch, California • Baldwin Park, California + 206 more
- Conditions
- Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Interventions
- cilengitide, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 19
- States / cities
- Oakland, California • San Francisco, California • Washington D.C., District of Columbia + 16 more